


# Daily Journal

APRIL 7, 2010

## Intellectual Property



The intellectual property space looms increasingly large in California's legal industry. As staff writer Craig Anderson writes, the Central District of California is now the largest IP venue in the nation. The Northern District, with its proximity to technology companies that fuel the nation's economic engine, also plays a crucial role. And then there is the Southern District, home to many of the nation's biotech companies.

lawyers are helping to draft and protect patents, trademarks and copyrights that bring us cleaner energy, faster technology, better medicine and more captivating entertainment.

Our process for selecting these lists — 75 IP Litigators, patent prosecutors and license specialists, — is two-fold. We solicit nominations from firms, agencies, corporate counsels and other interested parties. Our staff reporters also nominate lawyers based on cases they've covered. We look for lawyers whose work had the most impact on their client and more importantly on the area of law and the larger society. Read on, to see what we found.

We began this list three years ago to recognize lawyers in California who are working on the world's cutting edge issues. Across California,

— *The Editors*

### 25 PORTFOLIO MANAGERS, PROSECUTORS AND LICENSE SPECIALISTS



**NAN WU**  
COOLEY LLP  
SAN FRANCISCO

#### **Patent prosecution and portfolio management**

With a medical degree from Beijing Medical University, a Ph.D from Brown University, and a stint as a research fellow at Harvard Medical School, Wu prides herself not only on her scientific skills, but her business savvy as well.

Among her clients are Abaxis Inc., a Union City-based medical device company of which she is credited with helping to generate millions of dollars of royalty revenue; life science company Cypress BioSciences Inc.; and SciClone Pharmaceuticals Inc.

Wu also counsels venture capitalists on IP issues and portfolio assessment, and has served as the patent lead in various public securities filings and acquisitions.

"Last year, even though the economy was down, we had an increase in our business," Wu says.

"It's all about the patent."

"Companies realize that to do a high-value partnership deal, they have to have a strong patent position going in — knowing how many years of exclusivity you're going to get, and how many years you can keep generics out. That is the bottom line that translates to the value of the drugs."